Key Investor Information
Maple-Brown Abbott Asia-Ex Japan Fund (the “Fund”)
a sub-fund of Maple-Brown Abbott Funds p.l.c. (“the Company”)
Share Class: Institutional US Dollar      ISIN: IE00B284YV67

This document provides you with key investor information about this Fund. It is not marketing material. This information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

Objectives and Investment Policy

- The Fund aims to outperform the MSCI All Countries Asia Excluding Japan Net Index (US$) (the “Benchmark”) over rolling four year periods. There can be no guarantee that the investment objective of the fund will actually be achieved.
- The Fund is considered to be actively managed in reference to the Benchmark by virtue of the fact that it seeks to outperform the Benchmark and uses the Benchmark as a universe from which to select securities. The majority of the Fund’s securities may be components of the Benchmark, however the security and sector weightings are likely to diverge as Maple-Brown Abbott uses its discretion to take advantage of investment opportunities. The investment strategy and geographic focus of the Fund will restrict the extent to which the Fund’s holdings may deviate from the Benchmark. This is likely to influence the extent to which the Fund can outperform the Benchmark.
- It is intended that at least two thirds of its total assets will be invested in listed equities either directly in local markets, or indirectly through Global and American Depository Receipts ("GDRs" and "ADRs") listed on the European and North American stock exchanges. For the purpose of the Fund, Asia shall include China, Hong Kong, Taiwan, Singapore, Malaysia, Pakistan, Philippines, Thailand, South Korea, Indonesia and India. Generally, the companies it intends to invest in will have a market capitalisation greater than US$500 million.
- The Fund may engage in transactions in financial derivative instruments for investment and/or the purpose of efficient portfolio management. A derivative is a financial instrument whose value is based on the performance of another financial asset, index or investment.
- Although the use of derivatives (whether used for hedging or investment purposes) may give rise to additional exposure, this will not exceed the net asset value of the Fund.
- The Fund will seek to buy investments that offer relatively good long term value as measured by a number of traditional indicators.
- All income earned will be accumulated and reflected in the net asset value per share.
- This Fund may not be appropriate for investors who plan to withdraw their money within 4 years.
- Investors can buy, sell or switch shares daily.

For more information on the objectives and investment policy of the Fund please see the Prospectus at www.maple-brownabbott.com.au/ucits.

Risk and Reward Profile

- Lower risk
  - Typically lower rewards
  - The risk indicator has been created using historical data and may not be a reliable indication for the future risk profile of the Fund.
  - The risk category shown is not guaranteed and may change over time.
  - The lowest category does not mean risk free.

The Fund has been rated a six because the securities and instruments in which the Fund invests are subject to normal market fluctuations and other risks associated with investing in such investments and no guarantee can be given that their value will appreciate.

Materially relevant risks not adequately captured by the risk indicator include:
- Emerging market risk: A significant portion of the Fund’s assets may be invested in emerging markets which may have additional potential risks including lower regulatory standards, less developed settlement systems and economic and political instability.
- Market risk: Some of the Recognized Exchanges in which a Fund may invest may be less well-regulated than those in developed markets and may prove to be illiquid, insufficiently liquid or highly volatile from time to time. This may affect the price at which a Fund may liquidate positions to meet redemption requests or other funding requirements.
- International investment risk: The risk that changes in foreign exchange controls, imposition of confiscatory and withholding taxes, changes in government or economic monetary policy, appropriation of assets, political or economic instability, less rigorous financial reporting or auditing standards, potential difficulties enforcing rights and contractual obligations, and extended settlement periods have an adverse effect on the value of an investment.
- Currency risk: We invest in a number of countries. If the value of their currencies changes relative to other currencies in the Fund, the value of the investment can change.
- Liquidity risk: The Fund has the flexibility to invest a small portion of the portfolios capital in securities or investments that are not listed or rated and consequently liquidity in these investments may be lower.
- Counterparty risk. The Fund may be exposed to a credit risk in relation to the counterparties with whom they transact or place margin or collateral in respect of transactions in financial derivative instruments and may bear the risk of counterparty default.
- Derivatives risk: Derivatives involve the risk of mispricing or improper valuation and the risk that changes in the value of the derivative may not correlate perfectly with the underlying asset, rate or index.

For a more detailed explanation of these and other risks, please refer to the "Risk Factors" section of the Prospectus and Supplement for the Fund.
Charges for this Fund

The charges you pay are used to cover the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

| Charges taken from the Fund over the year | 1.00%<sup>(3)</sup> |
| One-off charges taken before or after you invest | Nil<sup>(1)</sup> |
| Entry charge | Nil<sup>(1)</sup> |
| Exit charge | 3%<sup>(2)</sup> |

This is the maximum that might be taken out of your money before it is invested or before proceeds of your investment paid out.

Charges taken from the Fund under certain specific conditions:

- Performance Fee: Nil

For more information on charges, please see the Prospectus, which is available at www.maple-brownabbott.com.au/ucits.

The entry and exit charges shown are the maximum figures. In some cases you might pay less – you can find this out from your financial adviser or the Distributor.

1. The Company reserves the right to impose “an anti-dilution levy” representing a provision for market spreads (the difference between the prices at which assets are valued and/or bought and sold), duties and charges and other dealing costs relating to the acquisition or disposal of assets and to preserve the value of the underlying assets of a Fund as a result of material net subscriptions or redemptions.
2. The exit fee has not been charged in the past and it is highly unlikely that it would ever be imposed.
3. The ongoing charges figure is capped at 1.00% p.a. The charges exclude portfolio transaction costs. Any amount above 1.00% p.a. will be paid by the Distributor.

Past Performance

Maple-Brown Abbott Asia-Ex Japan Fund Performance (in USD) as at 31 December 2019

The Fund was created in 2007 and this Share Class was launched in March 2017.

- Past performance is not a guide to future performance.
- The Fund’s performance is based on the movement in net asset value per share and is net of applicable tax and all fees and charges (excluding entry and exit charges).
- The graph shows the annual performance of the Fund in USD since inception in October 2007.
- Please note the performance chart was simulated from the actual performance of the Euro (unhedged) Share Class. This is because the two share classes do not differ materially in the extent of their participation in the assets of the Maple-Brown Abbott Asia-ex-Japan Fund, with the only difference being the calculation and reporting in the respective currency on an unhedged basis.

1. Benchmark: MSCI AC Asia ex-Japan Net Index in USD.

Practical Information

- Northern Trust Fiduciary Services (Ireland) Limited is the Depositary.
- Further information on the Fund together with copies of the latest annual and semi-annual reports and the Prospectus of the Company may be obtained (free of charge and in English) from the offices of the Distributor during normal business hours:

**Maple-Brown Abbott Limited**

Level 31, 259 George Street

Sydney NSW 2000

Australia

Tel: +61 2 8226 6200 or Fax: +61 2 8226 6201

E-mail: invest@maple-brownabbott.com.au

- Other practical information including latest net asset values are also available online at www.maple-brownabbott.com.au/ucits
- Details of the Company’s remuneration policy is available at www.maple-brownabbott.com.au/ucits and a paper copy will also be available free of charge upon request.

- Shareholders and potential investors should consult with their professional advisers in relation to the tax treatment of their holdings in the Company.
- The Company may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Company.
- The Fund is a sub-fund of Maple-Brown Abbott Funds p.l.c. The assets and liabilities of each sub-fund are segregated subject to the provisions of Irish law. However, these provisions have not been tested in other jurisdictions.
- Further information on how to convert shares in one Fund or Class to shares in another Fund or Class can be obtained from the Administrator, Northern Trust International Fund Administration Services (Ireland) Limited, or the Distributor.

This Key Investor Information Document (KIID) is specific to the Fund and Share Class detailed at the start of this document. The Prospectus and the annual and semi-annual reports cover all the sub-funds. Please visit www.maple-brownabbott.com.au/ucits for further information.

This Fund is authorized in Ireland and regulated by the Central Bank of Ireland.

This key investor information is accurate as at 19 February 2020.